Sign In
Last checked at 
16 Apr 2012 09:57
Annual Information Update
London, 16 April 2012. In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the period. The information referred to in this Update was up to date at the time the information was published, but some information may now be out of date.
Stock Exchange Announcements
Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/). The Stock Exchange announcements made during the period were:
Date of Announcement | Headline of Announcement |
13/04/2012 | Annual Financial Report & AGM Notice |
04/04/2012 | Company Secretary Change |
02/04/2012 | Total Voting Rights |
02/04/2012 | Blocklisting Interim Review |
28/03/2012 | Director/PDMR Shareholding |
19/03/2012 | Director/PDMR Shareholding |
16/03/2012 | Director/PDMR Shareholding |
14/03/2012 | Preliminary Results |
12/03/2012 | Holding(s) in Company |
14/02/2012 | Total Voting Rights |
02/02/2012 | Holding(s) in Company |
01/02/2012 | Director Declaration |
17/01/2012 | Tender Offer |
13/01/2012 | Director/PDMR Shareholding |
12/01/2012 | Total Voting Rights |
22/12/2011 | Additional Listing |
02/12/2011 | Tender Offer |
01/12/2011 | Holding(s) in Company |
11/11/2011 | Total Voting Rights |
04/11/2011 | Interim Management Statement |
24/10/2011 | Director/PDMR Shareholding |
18/10/2011 | Director/PDMR Shareholding |
18/10/2011 | Director/PDMR Shareholding |
18/10/2011 | Director/PDMR Shareholding |
17/10/2011 | Tender Offer |
07/10/2011 | Blocklisting Interim Review |
06/10/2011 | Dividend Declaration |
03/10/2011 | Acquisition |
25/08/2011 | Directorate Change |
25/08/2011 | Interim Results |
19/08/2011 | Trading Statement |
26/07/2011 | Total Voting Rights |
11/07/2011 | Hikma enhances its API sourcing capabilities |
01/06/2011 | Total Voting Rights |
26/05/2011 | Director/PDMR Shareholding |
25/05/2011 | Holding(s) in Company |
17/05/2011 | Director/PDMR Shareholding |
13/05/2011 | Director/PDMR Shareholding |
13/05/2011 | Dividend Declaration |
12/05/2011 | AGM Statement |
12/05/2011 | Interim Management Statement |
09/05/2011 | Director/PDMR Shareholding |
09/05/2011 | Total Voting Rights |
09/05/2011 | Annual Information Update |
03/05/2011 | Statement re Completion of Acquisition |
All of the above announcements were also made by the Company via the Nasdaq Dubai stock exchange CANDI system. These announcements may be viewed and downloaded from the Nasdaq Dubai website (www.candi.nasdaq.com).
Documents filed with the Financial Services Authority
The Company has filed the following documents with the Financial Services Authority ("FSA") visa the National Storage Mechanism over the previous 12 months. These documents are available at http://www.hemscott.com/nsm.do or at the Company's registered office.
Date | Document |
13 April 2012 | Annual Report and Accounts 2011 |
13 April 2012 | Notice of 2012 Annual General Meeting |
13 April 2012 | Proxy forms for the 2012 Annual General Meeting |
Documents filed with Companies House
The Company submitted filings to the Registrar of Companies in England and Wales as detailed in the table below.
Date Filed | Form | Description |
11/04/2012 | AP03 | Secretary Appointed, Peter Alexander Speirs |
11/04/2012 | TM02 | Secretary Appointment Terminated, Henry Knowles |
22/03/2012 | SH01 | 31/01/12 Statement of Capital GBP 19,586,621 |
22/03/2012 | SH01 | 22/03/12 Statement of Capital GBP 19,586,621 |
12/01/2012 | SH01 | 31/12/11 Statement of Capital GBP 19,582,971 |
28/11/2011 | SH01 | 31/10/11 Statement of Capital GBP 19,535,931 |
21/10/2011 | MG01 | Particulars of a Mortgage or Charge / Charge No: 1 |
19/09/2011 | RES01 | Adopt Articles 13/05/2010 |
19/09/2011 | CC04 | Statement of Company's Objects |
12/09/2011 | AR01 | 08/09/11 Full List |
02/09/2011 | AP01 | Director Appointed Robert Mark Pickering |
18/08/2011 | SH01 | 30/06/11 Statement of Capital GBP 19,533,781 |
29/06/2011 | SH01 | 31/05/11 Statement of Capital GBP 19,491,421 |
20/05/2011 | RES13 | Approval of Waiver 12/05/2011 |
19/05/2011 | AA | Group of Companies' Accounts Made up to 31/12/10 |
10/05/2011 | SH01 | 30/04/11 Statement of Capital GBP 19,485,361 |
Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House Direct at www.direct.companieshouse.gov.uk.
Further Information
Further information about Hikma Pharmaceuticals PLC can be found at our website www.hikma.com. Copies of all documents can be obtained from the Company at the registered office which is located at 13 Hanover Square, London W1S 1HW.
Peter Speirs
Company Secretary16 April 2012
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC | |
Peter Speirs Company Secretary
| +44 20 7399 2670 |
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non‐branded generic and in‐licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.
Follow the stocks
